These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12940439)

  • 21. Expression and significance of IGF-2, PCNA, MMP-7, and α-actin in gastric carcinoma with Lauren classification.
    Kuang RG; Wu HX; Hao GX; Wang JW; Zhou CJ
    Turk J Gastroenterol; 2013; 24(2):99-108. PubMed ID: 23934455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of serum soluble E-cadherin in colorectal carcinoma.
    Okugawa Y; Toiyama Y; Inoue Y; Iwata T; Fujikawa H; Saigusa S; Konishi N; Tanaka K; Uchida K; Kusunoki M
    J Surg Res; 2012 Jun; 175(2):e67-73. PubMed ID: 22277332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of transurethral resection of bladder tumour on serum levels of soluble E-cadherin.
    Durkan GC; Brotherick I; Mellon JK
    BJU Int; 1999 Mar; 83(4):424-8. PubMed ID: 10210565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems.
    Cho SJ; Choi IJ; Kook MC; Nam BH; Kim CG; Lee JY; Ryu KW; Kim YW
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1292-302. PubMed ID: 24134499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble E-cadherin as a serum biomarker candidate: elevated levels in patients with late-stage colorectal carcinoma and FAP.
    Weiss JV; Klein-Scory S; Kübler S; Reinacher-Schick A; Stricker I; Schmiegel W; Schwarte-Waldhoff I
    Int J Cancer; 2011 Mar; 128(6):1384-92. PubMed ID: 20473926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of E-cadherin in gastric carcinoma and its correlation with lymph node micrometastasis.
    Wu ZY; Zhan WH; Li JH; He YL; Wang JP; Lan P; Peng JS; Cai SR
    World J Gastroenterol; 2005 May; 11(20):3139-43. PubMed ID: 15918205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer.
    Shun CT; Wu MS; Lin JT; Wang HP; Houng RL; Lee WJ; Wang TH; Chuang SM
    Hepatogastroenterology; 1998; 45(22):944-9. PubMed ID: 9755986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Expressions of homeobox transcription factor-2 and E-cadherin in gastric carcinoma and their clinical significance].
    Ge J; Chen ZH; Chen ZK; Yuan WJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb; 28(2):279-1281. PubMed ID: 18250063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma.
    Harn HJ; Ho LI; Shyu RY; Yuan JS; Lin FG; Young TH; Liu CA; Tang HS; Lee WH
    J Clin Gastroenterol; 1996 Mar; 22(2):107-10. PubMed ID: 8742647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of the E-cadherin/catenin (alpha-, beta-, and gamma-) complex correlates with the macroscopic appearance of early gastric cancer.
    Ohene-Abuakwa Y; Noda M; Perenyi M; Kobayashi N; Kashima K; Hattori T; Pignatelli M
    J Pathol; 2000 Dec; 192(4):433-9. PubMed ID: 11113859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. E-cadherin expression as predictive marker of proximal resection line involvement for advanced carcinoma of the gastric cardia.
    Polkowski WP; Skomra DG; Mielko J; Wallner GT; Szumiło J; Zinkiewicz K; Korobowicz EM; van Lanschot JJ
    Eur J Surg Oncol; 2004 Dec; 30(10):1084-92. PubMed ID: 15522555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma.
    Han SU; Lee HY; Lee JH; Kim WH; Nam H; Kim H; Cho YK; Kim MW; Lee KU
    Ann Surg; 2005 Nov; 242(5):676-83. PubMed ID: 16244541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E-cadherin expression as a differentiation marker in gastric cancer.
    Karayiannakis AJ; Syrigos KN; Chatzigianni E; Papanikolaou S; Karatzas G
    Hepatogastroenterology; 1998; 45(24):2437-42. PubMed ID: 9951940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological Variation of Lauren Classification in Gastric Cancer.
    Chen YC; Fang WL; Wang RF; Liu CA; Yang MH; Lo SS; Wu CW; Li AF; Shyr YM; Huang KH
    Pathol Oncol Res; 2016 Jan; 22(1):197-202. PubMed ID: 26502923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of the serum level of soluble E-cadherin in patients with HCC.
    Soyama A; Eguchi S; Takatsuki M; Kawashita Y; Hidaka M; Tokai H; Nagayoshi S; Mochizuki S; Matsumoto S; Hamasaki K; Tajima Y; Kanematsu T
    Hepatogastroenterology; 2008; 55(85):1390-3. PubMed ID: 18795696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E-cadherin in gastric carcinomas related to histological prognostic parameters.
    Stănculescu D; Mărgăritescu C; Stepan A; Mitruţ AO
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1107-12. PubMed ID: 22119833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastric cancer: new genetic developments.
    Lynch HT; Grady W; Suriano G; Huntsman D
    J Surg Oncol; 2005 Jun; 90(3):114-33; discussion 133. PubMed ID: 15895459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy.
    Matsumoto K; Shariat SF; Casella R; Wheeler TM; Slawin KM; Lerner SP
    J Urol; 2003 Dec; 170(6 Pt 1):2248-52. PubMed ID: 14634390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum midkine concentrations and gastric cancer.
    Obata Y; Kikuchi S; Lin Y; Yagyu K; Muramatsu T; Kumai H;
    Cancer Sci; 2005 Jan; 96(1):54-6. PubMed ID: 15649256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.
    Rochefort P; Chabaud S; Pierga JY; Tredan O; Brain E; Bidard FC; Schiffler C; Polena H; Khalil-Mgharbel A; Vilgrain I; Bachelot T
    Br J Cancer; 2017 Jan; 116(3):356-361. PubMed ID: 28056463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.